1 August 2017 - Infliximab biosimilar to be dispensed predominately through hospitals.

MSD has today announced the availability of biosimilar Renflexis (infliximab) on the PBS from 1st August.

Renflexis is the second infliximab biosimilar to be PBS listed. Renflexis is indicated for the treatment of moderate to severe Crohn's disease and moderately severe to severe ulcerative colitis in adults and in children adolescents (6 to 17 years) who have had an inadequate response to conventional therapies. Renflexis is also indicated, in adults, for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, moderate to severe psoriasis and refractory fistulising Crohn's disease. Renflexis should be given in combination with methotrexate for the treatment of rheumatoid arthritis, and alone, or in combination with methotrexate, for the treatment of psoriatic arthritis.